Economists are projecting growth for the monthly comparisons in tomorrow’s April updates on residential housing construction and industrial output in the US. But while the consensus forecasts are calling for an encouraging start for the second-quarter data, the implied one-year
May 16, 2016
Oil prices pushed to their highest levels since November and fueled a nearly 200-point rally for the Dow Jones Industrial Average. The rally was a welcome one after a difficult few weeks for traders over concerns regarding the health and expected
Photo Credit: Mike Mozart The Home Depot, Inc. (HD) Consumer Discretionary – Specialty Retail | Reports May 17, Before Market Opens Key Takeaways The Estimize consensus is calling for earnings per share of $1.35 on $22.15 billion in revenue, 2 cents higher
Sweet Authoritative Nothings There is a mysterious figure making regular appearances in China’s government mouthpiece “People’s Daily”, which simply goes by the name “authoritative person” (AP). This unnamed entity always tends to show up with bad news for assorted speculators,
The Chart of the Day belongs to Parsley Energy (NYSE:PE). I found the oil exploration stock by using Barchart to sort today’s All Time High list first for the most frequent new highs in the last month, ten again for technical buy signals of 80% or
Here’s your swing-trading watch-list: Short Trimble Navigation (TRMB) Short Gamestop (GME) Short Olin (OLN) Long Akorn (AKRX) Long Williams Cos (WMB)
What if the FOMC and the wider Federal Reserve apparatus had heeded Greenspan’s uncertainty? There is grave danger in wandering too far into counterfactuals, but there is some value, I think, in the exercise in this context. What we are really
While it will hardly come as a shock following the turbulent events disclosed one week ago, which culminated with the “resignation” of CEO Renaud Laplanche, amid a series of complicated backdoor ‘related party’ transactions which could even implicate none other
Shares of Aduro Biotech (ADRO) tanked by 16.65% today after the company announced that it had failed its phase 2b “Eclipse” trial in patients with pancreatic cancer. The phase 2b trial was testing the company’s vaccine immunotherapy CRS-207, which is
Ira Epstein leads us through the day’s precious metal highlights. (Video length 00:07:03)
